Allosteric inhibitors of pyruvate kinase
US6534501B2 · kind B2 · utility
22Cited by
6References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 7, 2001 |
| Grant date | Mar 18, 2003 |
| Priority date | — |
| Expiry date | Mar 7, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/325
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.